Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current

News

argenx Data Shows Evidence That VYVGART And VYVGART Hytrulo Deliver Transformative Results For Patients Suffering From Debilitating Autoimmune Diseases

Author: Benzinga Newsdesk | April 16, 2024 03:18am

ADHERE data show VYVGART® Hytrulo has potential to be first advancement for CIDP patients in 30 years

Real-world data demonstrate gMG patients able to significantly reduce steroid use over first six months of initiating VYVGART® treatment

Posted In: ARGX

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist